Clinical trial

Impact of GLP-1 Receptor Agonists on Patients With IPMN

Opening soon · Not applicable · 1 countries · Registry ID NCT07014709

Opening soonNot applicableObservational

What this study is about

This study investigates the impact of GLP-1 receptor agonists (GLP-1 RAs) on patients with intraductal papillary mucinous neoplasms (IPMNs), a type of pancreatic cystic neoplasm that can progress to malignancy. With the increasing use of GLP-1 RAs for managing diabetes and obesity, concerns about their potential to influence pancreatic conditions, like IPMNs, have emerged. Although GLP-1 RAs are generally safe, their effects on pre-existing pancreatic conditions remain unclear. The study aims to evaluate whether GLP-1 RA use in IPMN patients is linked to changes in pancreatic cyst characteristics, the incidence of acute pancreatitis, variations in tumor markers, and the progression of IPMNs to high-grade dysplasia or malignancy. A retrospective analysis will be conducted using medical data from patients diagnosed with IPMNs and treated with GLP-1 RAs between 2010 and 2024 at three Swiss hospitals. Key outcomes will include radiological changes, the incidence of acute pancreatitis, and potential shifts in IPMN surveillance or need for surgical intervention

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to Not listed

SexAll

Healthy volunteersNot accepted

ConditionIPMN, IPMN, Pancreatic, GLP-1, Intraductal Papillary Mucinous Neoplasm of Pancreas, Glucagon-Like Peptide-1 Receptor Agonists

Full registry criteria

Inclusion Criteria: * \> 18 years old * Radiological diagnosis of IPMN * Treated with GLP-1 RAs. * Patients must have provided prior informed consent for the use of their coded clinical data in research. Exclusion Criteria: * radiological diagnosis of IPMN is unclear, * no documented history of GLP-1 RAs use * patients did not provide signed informed consent, or have documented refusal for research.

Treatments and study arms

GLP1 receptor agonist

Drug

Patients must be under GLP1-RA treatment for ether diabetes or obesity

Primary outcomes

Radiological changes in pancreatic cyst characteristic as described in the Kyoto 2023 Consensusduring the GLP1 RA treatment

Radiological data, including data from MRI scans, will be used to monitor changes in IPMN characteristics. If only CT scans are available, they will also be evaluated, even if this is not the preferred imaging method for IPMN evaluation

Study locations

1 locations were listed when this page was built. The first 40 are shown.

HFR Hopital fribourgeois🇨🇭 Villars-sur-Glâne, Switzerland

Open map

Melissa LaggerContact

Email · Call +41263062608

Léo Buhler, Prof.Contact

Email · Call +41263062510

Michel Adamina, ProfPrincipal Investigator